Department of Physiology (392), Radboud Institute for Health Sciences, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
Department of Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Sports Med. 2017 Sep;47(9):1885-1892. doi: 10.1007/s40279-017-0681-7.
HMG-CoA reductase inhibitors (statins) are the first-choice therapy for primary prevention of cardiovascular disease. Some maintain that statins cause adverse musculoskeletal outcomes in highly active individuals, but few studies have examined the effects of statins on exercise-related injuries.
We sought to compare the prevalence of exercise-related injuries between runners who do or do not use statins.
Amateur runners (n = 4460) completed an extensive online questionnaire on their exercise patterns and health status. Participants replied to questions on the prevalence of exercise-related injuries in the previous year. Injuries were divided into general injuries, tendon- and ligament-related injuries, and muscle-related injuries. Participants were also queried about statin use: the type of statin, statin dose, and duration of treatment. Runners were divided into statin users, non-statin users with hypercholesterolemia, and controls for analysis.
The crude odds ratios (ORs) for injuries, tendon- or ligament-related injuries, and muscle-related injuries in statin users compared with controls were 1.14 (95% confidence interval [CI] 0.79-1.66), 1.10 (95% CI 0.71-1.72), and 1.15 (95% CI 0.69-1.91), respectively. After adjustment for age, sex, body mass index (BMI), and metabolic equivalent of task (MET) h/week of exercise, the ORs were 1.11 (95% CI 0.76-1.62), 1.06 (95% CI 0.68-1.66), and 0.98 (95% CI 0.58-1.64), respectively. Similar effect measures were found when comparing non-statin users with hypercholesterolemia and controls.
We did not find an association between statin use and the prevalence of exercise-related injuries or tendon-, ligament-, and muscle-related injuries. Runners receiving statins should continue normal physical activity without concern for increased risk of injuries.
羟甲基戊二酰辅酶 A 还原酶抑制剂（他汀类药物）是预防心血管疾病的首选药物。有人认为他汀类药物会导致高度活跃人群出现不良的肌肉骨骼结果，但很少有研究检查他汀类药物对与运动相关的损伤的影响。
我们旨在比较使用和不使用他汀类药物的跑步者中与运动相关的损伤的发生率。
业余跑步者（n=4460）完成了一份关于他们运动模式和健康状况的广泛在线问卷。参与者回答了关于前一年与运动相关的损伤的流行率的问题。损伤分为一般损伤、肌腱和韧带相关损伤以及肌肉相关损伤。还询问了参与者他汀类药物的使用情况：他汀类药物的类型、他汀类药物的剂量和治疗时间。跑步者被分为他汀类药物使用者、胆固醇升高的非他汀类药物使用者和对照组进行分析。
与对照组相比，他汀类药物使用者的损伤、肌腱或韧带相关损伤和肌肉相关损伤的粗比值比（OR）分别为 1.14（95%置信区间 [CI] 0.79-1.66）、1.10（95% CI 0.71-1.72）和 1.15（95% CI 0.69-1.91）。调整年龄、性别、体重指数（BMI）和运动的代谢当量（MET）小时/周后，OR 分别为 1.11（95% CI 0.76-1.62）、1.06（95% CI 0.68-1.66）和 0.98（95% CI 0.58-1.64）。当将非他汀类药物使用者与高胆固醇血症和对照组进行比较时，也发现了相似的效应度量。
我们没有发现他汀类药物使用与与运动相关的损伤或肌腱、韧带和肌肉相关损伤的发生率之间存在关联。服用他汀类药物的跑步者应继续正常的体育活动，而不必担心增加受伤的风险。
